We are live on
!
Find out more
CM
CM Management Portfolio holdings
AUM
$157M
Turnover
30.95%
1-Year Est. Return
60.08%
This Fund
S&P 500
This Quarter
Est. Return
+3.82%
1 Year Est. Return
+60.08%
3 Year Est. Return
+110.48%
5 Year Est. Return
+186.03%
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$5.38M
(-4.3%)
Cap. Flow
-$5.42M
Cap. Flow
% of AUM
-4.55%
Top 10 Holdings %
Top 10 Hldgs %
36.72%
Holding
80
New
8
Increased
27
Reduced
7
Closed
11
Avg Time Held
1.7
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$1.8M |
| 2 |
Walgreens Boots Alliance
WBA
|
+$1.67M |
| 3 |
Baidu
BIDU
|
+$1.6M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$1.53M |
| 5 |
Alibaba
BABA
|
+$1.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunogen Inc
IMGN
|
+$14.8M |
| 2 |
National Healthcare
NHC
|
+$2.77M |
| 3 |
Carrols Restaurant Group, Inc.
TAST
|
+$2.76M |
| 4 |
Freeport-McMoran
FCX
|
+$2.13M |
| 5 |
BGC Group
BGC
|
+$1.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.71% |
| 2 | Industrials | 9.53% |
| 3 | Technology | 8.54% |
| 4 | Materials | 8.18% |
| 5 | Consumer Staples | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Tejon Ranch
TRC
$446M
| $693K | 0.58% |
45,000
+5,000
| +13% | +$80.9K |
2020 Q4
13 quarters
|
|
52
Femasys
FEMY
$14.2M
| $620K | 0.52% |
20,000
-2,500
| -11% | -$65.6K |
2021 Q2
11 quarters
|
|
53
Compass Therapeutics
CMPX
$157M
| $614K | 0.52% |
310,000
+185,000
| +148% | +$320K |
2023 Q4
1 quarter
|
|
54
Lantern Pharma
LTRN
$9.5M
| $572K | 0.48% |
65,000
-15,000
| -19% | -$80.2K |
2022 Q1
8 quarters
|
|
55
Elicio Therapeutics
ELTX
$45.5M
| $570K | 0.48% |
75,000
+25,000
| +50% | +$125K |
2021 Q1
12 quarters
|
|
|
VRNA
56
DELISTED
Verona Pharma
VRNA
| $563K | 0.47% |
+35,000
| New | +$605K |
2024 Q1
0 quarters
|
|
57
First Financial Corp
THFF
$878M
| $537K | 0.45% |
+14,000
| New | +$543K |
2024 Q1
0 quarters
|
|
58
Bristow Group
VTOL
$1.14B
| $418K | 0.35% |
+15,377
| New | +$410K |
2024 Q1
0 quarters
|
|
59
Gain Therapeutics
GANX
$55.4M
| $339K | 0.29% |
90,000
| – | – |
2021 Q2
11 quarters
|
|
60
DELISTED
Assertio
ASRT
| $331K | 0.28% |
23,000
| – | – |
2023 Q2
3 quarters
|
|
61
Eledon Pharmaceuticals
ELDN
$178M
| $330K | 0.28% |
160,000
+20,000
| +14% | +$35.7K |
2021 Q1
12 quarters
|
|
62
DELISTED
Kronos Bio
KRON
| $325K | 0.27% |
250,000
| – | – |
2022 Q4
5 quarters
|
|
63
Cognition Therapeutics
CGTX
$68.7M
| $319K | 0.27% |
+175,000
| New | +$361K |
2024 Q1
0 quarters
|
|
64
DELISTED
Cadence Bank
CADE
| $290K | 0.24% |
10,000
| – | – |
2023 Q2
3 quarters
|
|
65
BioCardia
BCDA
$13.8M
| $285K | 0.24% |
46,667
| – | – |
2020 Q4
13 quarters
|
|
66
Edesa Biotech
EDSA
$25.1M
| $260K | 0.22% |
62,000
| – | – |
2022 Q3
6 quarters
|
|
67
Smith Micro Software
SMSI
$13M
| $207K | 0.17% |
15,000
| – | – |
2020 Q4
13 quarters
|
|
68
Cartesian Therapeutics
RNAC
$193M
| $199K | 0.17% |
10,183
-13,150
| -56% | -$279K |
2020 Q4
13 quarters
|
|
69
Palvella Therapeutics
PVLA
$1.71B
| $105K | 0.09% |
7,188
-2,187
| -23% | -$30.5K |
2023 Q2
3 quarters
|
|
70
APA Corp
APA
$17B
| – | – |
-25,000
| Closed | -$897K | – |
|
|
71
Freeport-McMoran
FCX
$101B
| – | – |
-50,000
| Closed | -$2.13M | – |
|
72
Fidelity National Information Services
FIS
$18.5B
| – | – |
-17,500
| Closed | -$1.05M | – |
|
73
Fidelity National Financial
FNF
$10.7B
| – | – |
-25,000
| Closed | -$1.28M | – |
|
|
74
National Healthcare
NHC
$3.8B
| – | – |
-30,000
| Closed | -$2.77M | – |
|
75
DELISTED
Vital Energy
VTLE
| – | – |
-15,000
| Closed | -$682K | – |
|
Similar funds
SFSG
PTFIS
AWMG
LDNAM
DFS
APW
GA
TC
CM Management's Q1 2024 Portfolio in Review
As of Q1 2024, CM Management held 80 positions worth $119M, down 4.3% from $124M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
CM Management withdrew a net $5.42M in Q1 2024, closing 11 positions and reducing 7 holdings. Its most notable exit was Immunogen Inc, an estimated $14.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier, followed by Industrials and Technology.
Against the trend, CM Management opened a new position in Incyte worth $1.71M.
- CM Management's largest Q1 2024 buy was Incyte: 30,000 shares worth $1.71M.
- CM Management added most to Walgreens Boots Alliance in Q1 2024, an estimated $1.67M increase.
- CM Management's biggest Q1 2024 reduction was BGC Group, cutting an estimated $1.85M.
- CM Management fully exited Immunogen Inc in Q1 2024, selling an estimated $14.8M.
- CM Management's ten largest holdings make up 37% of its $119M portfolio in Q1 2024.
- CM Management opened 8 new positions and closed 11 in Q1 2024.
- CM Management's portfolio value fell 4.3% quarter-over-quarter to $119M.
Based on CM Management's 13F filing for Q1 2024, filed 14 May 2024.